Is it bad to take melatonin every night?

Millions of people take melatonin before bed each night and quietly wonder whether they're doing something they shouldn't be. The concern is understandable — melatonin is a hormone, and taking any hormone supplement regularly raises legitimate questions about what happens over time. Melatonin use among U.S. adults more than quintupled between 1999 and 2018, yet long-term safety research has struggled to keep pace with that growth. The short answer, based on the best available evidence, is that nightly melatonin at low-to-moderate doses is safe for most healthy adults — but dose, delivery method, and individual context all determine whether the answer applies to you.

What the Research Actually Says About Nightly Melatonin

The research on nightly melatonin, taken as a whole, is reassuring for most adults using low-to-moderate doses. Melatonin use among U.S. adults increased from 0.4% of the population in 1999–2000 to 2.1% in 2017–2018 — a more than fivefold rise documented across 55,021 adults in the NHANES survey, published in JAMA in 2022. High-dose use (above 5 mg/day) remained very low at 0.28%, meaning the vast majority of users were taking amounts within the ranges studied in clinical trials.

The most rigorous trial on this question followed 244 adults with primary insomnia through 6 to 12 months of nightly prolonged-release melatonin (2 mg). Published in Therapeutic and Clinical Risk Management, it found no tolerance, no withdrawal or rebound insomnia after discontinuation at 12 months, no suppression of natural melatonin production, and sustained or improving sleep quality across the study period. A separate 6-month randomized, placebo-controlled study in 791 adults aged 18–80 confirmed that early sleep improvements were maintained over 26 weeks with adverse events comparable to placebo.

These trials underpin the consensus of a 2023 narrative review in Nutrients: melatonin at low-to-moderate doses (approximately 5–6 mg/day or less) appears safe for most adults with long-term use, though trials extending beyond 12 months remain limited. Available evidence does not show harm from nightly melatonin in healthy adults at appropriate doses — but the evidence base is smaller than it would be for a fully regulated pharmaceutical. That gap is worth knowing about.

Does Nightly Melatonin Suppress Your Natural Production?

One of the most common fears about nightly melatonin is that it might train your pineal gland to stop producing its own melatonin, making you permanently dependent on supplements. This concern is biologically understandable — many hormones operate on negative feedback loops that external supplementation can suppress. Melatonin works differently.

Your pineal gland produces melatonin in response to light and dark signals transmitted through the retina and suprachiasmatic nucleus (SCN) — not in response to circulating melatonin levels. There is no significant negative feedback mechanism through which melatonin suppresses its own production the way testosterone does. The MT1 and MT2 receptors that melatonin binds to do not trigger the kind of feedback suppression seen with other hormones.

Clinical evidence supports this. In the 6–12 month nightly use trial described above, nocturnal urinary 6-sulfatoxymelatonin — a direct measure of endogenous production — was assessed after stopping treatment. Production was not suppressed; levels were indistinguishable from normal age-matched values. The majority of studies on this question conclude that supplementation does not suppress endogenous production even with up to one year of daily use, though data beyond 12 months remains limited. Circadian melatonin rhythms in separate research recovered to normal within three days of stopping supplementation — consistent with production being light-driven, not feedback-suppressed.

Psychological dependence is a separate issue and a real one. Some people who take melatonin nightly develop habitual reliance even when the physiological need is absent. This is behavioral, not pharmacological, and can be assessed with a planned melatonin-free trial period. For more on this distinction, see the BioAbsorb guide to melatonin tolerance and dependency.

The Real Risks That Do Exist — and How to Avoid Them

Saying nightly melatonin is generally safe is not the same as saying it is risk-free at any dose, at any time, or for any person. Several real risks are documented in the clinical literature, and most of them are preventable with better dosing and timing practices.

Morning grogginess is the most common problem — and it is almost always dose-related. Systematic reviews of safety data from randomized, placebo-controlled trials report daytime sleepiness as an adverse effect in only 1.66% of patients versus placebo — a low rate. However, this rate climbs significantly with higher doses. Melatonin blood levels from a standard 5 mg tablet can run 10 to 100 times higher than what the body naturally produces at night, and levels that are still elevated at wake time produce the "melatonin hangover" that many people experience. The solution is not to stop taking melatonin — it is to reduce the dose. Research consistently shows that 0.5–3 mg is sufficient for most adults, and that doses above 5 mg provide no additional sleep benefit while substantially increasing side effect risk.

Supplement label inaccuracy is a risk most people don't know exists. An important study found that melatonin content in commercially available supplements varied from 83% to 478% of the labelled dose across products. This means that a "1 mg" tablet from an untested brand could actually deliver nearly 5 mg — and a "5 mg" tablet could deliver the equivalent of 24 mg. This is not a theoretical concern; it is a documented quality control failure in the supplement industry. Third-party tested products are meaningfully safer because the dose on the label reflects what is actually in the product.

Vivid dreams can increase with nightly use, particularly at higher doses. This is a recognized effect linked to melatonin's influence on REM sleep architecture. For most people it is a nuisance rather than a serious concern, but for people who are sensitive to disturbing dream content it can be significant enough to warrant dose reduction or discontinuation.

Drug interactions are real and clinically relevant. Melatonin is metabolized by the liver enzyme CYP1A2. Medications that inhibit this enzyme — including fluvoxamine (an antidepressant) — can dramatically increase melatonin blood levels. Melatonin also interacts with blood thinners, blood pressure medications, diabetes drugs, immunosuppressants, and CNS depressants. If you take any prescription medications and use melatonin nightly, a conversation with your prescribing physician is not optional — it is necessary. For a full breakdown, see the BioAbsorb melatonin drug interactions guide.

Autoimmune conditions warrant caution. Melatonin has immunomodulatory effects and may stimulate immune function. For people on immunosuppressive therapy, this can interfere with treatment. The Mayo Clinic specifically recommends against melatonin use in people with autoimmune diseases. This is one of the few absolute contraindications that is widely cited in clinical guidance.

For a complete picture of melatonin's side effect profile, see the BioAbsorb guide to the bad side effects of melatonin and the broader melatonin side effects and safety guide.

Who Should Not Take Melatonin Every Night

Pregnant and breastfeeding women should not use melatonin due to insufficient safety data. Melatonin crosses the placental barrier and is secreted in breast milk, and its effects on fetal and infant development have not been adequately studied.

Children and adolescents present a more nuanced picture. Melatonin is used clinically in children with autism spectrum disorder and ADHD, often with good outcomes. However, questions about the effects of prolonged supplementation on pubertal timing remain unresolved — melatonin declines naturally during adolescence in a pattern that parallels sexual maturation, and long-term supplementation during this period has not been fully studied. Pediatric nightly use should always involve a healthcare provider.

People with liver impairment metabolize melatonin more slowly, producing higher and longer-lasting blood levels at standard doses. People with poorly controlled diabetes should be cautious, as melatonin can affect glucose tolerance and insulin sensitivity. People on sedative or CNS depressant medications can experience intensified additive sedation — combining these with melatonin should only happen under medical guidance. People with autoimmune diseases should avoid melatonin, as its immunomodulatory effects may interfere with immunosuppressive therapy — this is among the few absolute contraindications cited consistently in clinical guidance.

Why Dose and Delivery Method Change Everything

Most of the problems people attribute to nightly melatonin — morning grogginess, ineffectiveness, vivid dreams — trace back not to nightly use itself, but to nightly use of the wrong dose in the wrong form.

The commercially available doses in the U.S. are wildly misaligned with what the research supports. Standard pharmacy tablets run 5 mg to 10 mg, yet MIT research and subsequent studies have consistently found that physiological doses — as low as 0.3 mg — are sufficient to shift circadian timing and facilitate sleep onset. A dose-response meta-analysis covering 26 randomized controlled trials and 1,689 participants found that sleep benefit peaks around 4 mg/day, with diminishing returns above that and no clinical advantage at the higher doses commonly sold over the counter. The effective therapeutic range for most adults is 0.5–3 mg.

What happens above that range is not neutral. Blood melatonin levels from a 5 mg tablet can run 10 to 100 times above natural nighttime peaks. High circulating melatonin at the time of waking is the primary mechanism behind morning grogginess. Reducing the dose is far more effective than stopping altogether.

Delivery method compounds this problem. Standard oral tablets pass through the digestive tract and undergo significant first-pass liver metabolism via the CYP1A2 enzyme, resulting in variable oral bioavailability — research estimates range from 10% to 56% of the labelled dose reaching systemic circulation. This variability means two people taking the same 5 mg tablet may experience very different blood levels and very different effects.

Liposomal delivery systems encapsulate melatonin in phospholipid spheres that begin absorbing through the mucosal lining of the mouth and gastrointestinal tract, substantially bypassing first-pass metabolism. Bioavailability estimates for properly manufactured liposomal melatonin reach 80–95%. This means a 1 mg liposomal dose may deliver more melatonin to the bloodstream than a 5 mg standard tablet — enabling more precise, lower-dose supplementation with more consistent results and fewer side effects. Understanding this distinction is one of the most important things a nightly melatonin user can know. The BioAbsorb article on melatonin bioavailability and absorption covers this science in depth, and the BioAbsorb dosage guide provides practical guidance on finding your effective dose.

Timing is the third variable. Taking melatonin too late — rather than 30–90 minutes before target bedtime — means blood levels are still elevated at wake time, which causes grogginess. For timing guidance specific to different use cases, see the BioAbsorb timing protocol.

How BioAbsorb Approaches Nightly Melatonin Use

At BioAbsorb Nutraceuticals, we designed our Liposomal Liquid Melatonin specifically around what the research says about dose and delivery — not around what is convenient to manufacture or easy to market.

Most melatonin products on the market start at 5 mg tablets. The research is clear that this is higher than most adults need, higher than the dose that produces peak sleep benefit in meta-analyses, and high enough to reliably produce morning grogginess in a meaningful proportion of users. The liposomal liquid format we use exists specifically to solve this problem: higher bioavailability through a superior delivery mechanism means effective results at lower doses, with a graduated dropper that allows precise titration. You can start low — as the research recommends — and adjust in small increments until you find what works for you.

Our product is manufactured in a GMP-certified facility with third-party testing, which addresses the label accuracy problem that affects a significant portion of the supplement market. When you take a dose, the amount on the label reflects what is actually in the product.

BioAbsorb's approach to nightly melatonin use aligns with what the evidence supports: low dose, precision delivery, and consistent timing — not the highest number on the label. If you are new to melatonin or currently experiencing morning grogginess from your current product, starting with a lower dose in a higher-bioavailability format is the change most likely to make a difference. See the full guide to what melatonin is and how it works for the foundational science behind these principles.

Frequently Asked Questions

Is it okay to take melatonin every night for months or years?

The best available clinical evidence — including a 6–12 month randomized trial in 244 insomnia patients and a 6-month trial in 791 adults — supports that nightly melatonin at low-to-moderate doses is safe without development of tolerance, withdrawal symptoms, or suppression of natural production. Trials extending beyond 12 months remain limited, and long-term use should include periodic reassessment of whether it is still needed. Most physicians recommend an annual review even for patients who intend to continue indefinitely.

Will melatonin stop working if I take it every night?

Clinical trials show that effectiveness does not diminish with continuous nightly use — in fact, the 6–12 month trial found that sleep quality improvements were maintained or enhanced over time with no evidence of tolerance. If melatonin seems to stop working for you, the more likely explanations are a change in your underlying sleep issue (such as a shift from sleep-onset to sleep-maintenance insomnia), new stress, new medications, or the need to recalibrate dose or timing. An increase in dose is often not the right response — and may worsen the problem.

Can taking melatonin every night cause hormone imbalances?

At the doses used for sleep (0.5–5 mg), no clinically significant hormonal disruption has been consistently identified in healthy adults. The concern about melatonin disrupting reproductive hormones is primarily a pediatric question — particularly for prepubertal children — where research on long-term effects is still evolving. In adults, the hormonal effects of melatonin at sleep doses are considered minor by the available evidence, though people with pre-existing hormonal conditions or those on hormone-modulating medications should discuss with their physician before using melatonin nightly.

Why do I feel groggy the morning after taking melatonin?

Morning grogginess after melatonin is almost always caused by one or both of two things: the dose is too high, or the timing is too late. When blood melatonin levels are still elevated at wake time — which happens more with higher doses and late-night administration — the sleep-promoting signal has not fully cleared. The solution in most cases is a dose reduction (try 0.5–1 mg instead of 5–10 mg) and taking it earlier in the evening. Switching to a higher-bioavailability format like liposomal liquid also helps, because you can achieve the same circadian effect with a meaningfully lower dose.

Are there any people who should never take melatonin every night?

Yes. Pregnant and breastfeeding women should avoid nightly melatonin due to insufficient safety data. People with autoimmune diseases should avoid it because melatonin may interfere with immunosuppressive therapy. People on certain medications — particularly fluvoxamine, blood thinners, blood pressure drugs, anticonvulsants, and CNS depressants — should consult a physician before regular use due to interaction risk. People with liver impairment may metabolize melatonin more slowly, which changes the effective dose substantially.

Is there a best form of melatonin for nightly use?

For nightly use, the most important factors are dosing precision and consistent bioavailability. Standard tablets have variable oral bioavailability (10–56%) and lack dose flexibility. Liposomal liquid formulations offer substantially higher bioavailability (80–95%) and allow precise small-increment dosing, making it easier to stay in the effective low-dose range that research supports. For most nightly users, a high-bioavailability format taken at a low dose produces better results with fewer side effects than the high-dose tablets that dominate pharmacy shelves.

Conclusion

Is it bad to take melatonin every night? For most healthy adults using appropriate doses of a quality product, the evidence says no — nightly melatonin does not cause tolerance, does not suppress your body's own production, and does not produce clinically significant harm at low-to-moderate doses. The risks that do exist — morning grogginess, drug interactions, label inaccuracy, suitability for specific health conditions — are real but largely manageable with informed choices. The biggest risk is not taking melatonin every night. It is taking too much melatonin, in the wrong form, without awareness of who should avoid it.

If you are using melatonin nightly and it is working, low-dose and high-quality is the approach most aligned with the research. If you are struggling with morning grogginess or inconsistent results, the first step is dose reduction and delivery method review — not stopping altogether. Explore BioAbsorb Liposomal Liquid Melatonin for precision dosing designed around what the science actually supports.

Research References

1. Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in use of melatonin supplements among US adults, 1999–2018. JAMA. 2022;327(5):483–485. doi:10.1001/jama.2021.23652. PubMed
2. Besag FMC, Vasey MJ, Lao KSJ, Wong ICK. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs. 2019;33(12):1167–1186. doi:10.1007/s40263-019-00680-w. PubMed
3. Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N. Prolonged-release melatonin for insomnia — an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011;7:301–311. doi:10.2147/TCRM.S23036. PubMed
4. Wade AG, Crawford G, Ford I, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial. BMC Med. 2010;8:51. doi:10.1186/1741-7015-8-51. PubMed
5. Savage RA, Zafar N, Yohannan S, Miller JMM. Melatonin. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. NCBI Bookshelf
6. Andersen LPH, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. Clin Drug Investig. 2016;36(3):169–175. doi:10.1007/s40261-015-0368-5. PubMed
7. Arendt J. Safety of melatonin in long-term use (?). J Biol Rhythms. 1997;12(6):673–681. doi:10.1177/074873049701200624. PubMed
8. Erland LAE, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–281. doi:10.5664/jcsm.6462. PubMed
9. Costello RB, Lentino CV, Boyd CC, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J. 2014;13:106. doi:10.1186/1475-2891-13-106. PubMed
10. Lim S, Park S, Koyanagi A, Yang JW. Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials. Pharmacol Res. 2022;176:106080. doi:10.1016/j.phrs.2021.106080. ScienceDirect
11. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. NEJM. Published correction: Benloucif S, Guico MJ, Reid KJ, et al. Stability of melatonin and temperature as circadian phase markers and their relation to sleep times in humans. J Biol Rhythms. 2005;20(2):178–188. PubMed
12. Menczel Schrire Z, Phillips CL, Chapman JL, et al. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis. J Pineal Res. 2022;72(2):e12782. doi:10.1111/jpi.12782. Journal of Pineal Research
13. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773. doi:10.1371/journal.pone.0063773. PubMed
14. Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434–443. doi:10.2174/1570159X14666161228122115. PubMed
15. Seabra ML, Bignotto M, Pinto LR, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29(4):193–200. doi:10.1034/j.1600-0633.2002.290401.x. PubMed
16. Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014;37(10):1715–1719. doi:10.5665/sleep.4088. PubMed
17. Borrmann H, Brandmaier S, Koutsouleris N, et al. Optimizing the time and dose of melatonin as a sleep-promoting drug: a systematic review of randomized controlled trials and dose-response meta-analysis. J Pineal Res. 2024;76(4):e12985. doi:10.1111/jpi.12985. PubMed
18. National Institutes of Health. Use of melatonin supplements rising among adults. NIH Research Matters. 2022. NIH.gov

---

Author Bio
David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

Medical Disclaimer
This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing. Individual responses to melatonin vary, and the information presented here reflects general findings from published research and is not a substitute for personalized medical guidance.

FDA/Health Canada Statement
These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.